Human Polo-like Kinase Inhibitors as Antiplasmodials

ACS Infect Dis. 2023 Apr 14;9(4):1004-1021. doi: 10.1021/acsinfecdis.3c00025. Epub 2023 Mar 15.

Abstract

Protein kinases have proven to be a very productive class of therapeutic targets, and over 90 inhibitors are currently in clinical use primarily for the treatment of cancer. Repurposing these inhibitors as antimalarials could provide an accelerated path to drug development. In this study, we identified BI-2536, a known potent human polo-like kinase 1 inhibitor, with low nanomolar antiplasmodial activity. Screening of additional PLK1 inhibitors revealed further antiplasmodial candidates despite the lack of an obvious orthologue of PLKs in Plasmodium. A subset of these inhibitors was profiled for their in vitro killing profile, and commonalities between the killing rate and inhibition of nuclear replication were noted. A kinase panel screen identified PfNEK3 as a shared target of these PLK1 inhibitors; however, phosphoproteome analysis confirmed distinct signaling pathways were disrupted by two structurally distinct inhibitors, suggesting PfNEK3 may not be the sole target. Genomic analysis of BI-2536-resistant parasites revealed mutations in genes associated with the starvation-induced stress response, suggesting BI-2536 may also inhibit an aminoacyl-tRNA synthetase.

Keywords: NEK; PLK; Plasmodium; antimalarial; antiplasmodial; kinase; malaria.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Antimalarials* / pharmacology
  • Cell Cycle Proteins / genetics
  • Cell Cycle Proteins / metabolism
  • Humans
  • Protein Kinase Inhibitors / pharmacology
  • Protein Serine-Threonine Kinases / genetics

Substances

  • polo-like kinase 1
  • Antimalarials
  • Protein Kinase Inhibitors
  • Protein Serine-Threonine Kinases
  • Cell Cycle Proteins